- Home
- ALTS vs QNCX Comparison
ALTS vs QNCX Comparison
Compare ALTS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- QNCX
- Stock Information
- Founded
- ALTS 1976
- QNCX 2012
- Country
- ALTS United States
- QNCX United States
- Employees
- ALTS N/A
- QNCX N/A
- Industry
- ALTS
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALTS
- QNCX Health Care
- Exchange
- ALTS NYSE
- QNCX Nasdaq
- Market Cap
- ALTS 84.1M
- QNCX 70.4M
- IPO Year
- ALTS N/A
- QNCX 2019
- Fundamental
- Price
- ALTS $5.93
- QNCX $1.60
- Analyst Decision
- ALTS
- QNCX Strong Buy
- Analyst Count
- ALTS 0
- QNCX 4
- Target Price
- ALTS N/A
- QNCX $9.50
- AVG Volume (30 Days)
- ALTS 228.6K
- QNCX 139.9K
- Earning Date
- ALTS 11-12-2024
- QNCX 03-31-2025
- Dividend Yield
- ALTS N/A
- QNCX N/A
- EPS Growth
- ALTS N/A
- QNCX N/A
- EPS
- ALTS N/A
- QNCX N/A
- Revenue
- ALTS $7,110,000.00
- QNCX N/A
- Revenue This Year
- ALTS N/A
- QNCX N/A
- Revenue Next Year
- ALTS N/A
- QNCX N/A
- P/E Ratio
- ALTS N/A
- QNCX N/A
- Revenue Growth
- ALTS N/A
- QNCX N/A
- 52 Week Low
- ALTS $0.60
- QNCX $0.51
- 52 Week High
- ALTS $7.09
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ALTS 56.75
- QNCX 43.92
- Support Level
- ALTS $5.84
- QNCX $1.49
- Resistance Level
- ALTS $6.64
- QNCX $1.69
- Average True Range (ATR)
- ALTS 0.65
- QNCX 0.14
- MACD
- ALTS -0.01
- QNCX 0.00
- Stochastic Oscillator
- ALTS 71.10
- QNCX 46.15
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.